The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of β-hexosaminidase from skin slices in vitro
- 2 January 2006
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 78 (6), 598-606
- https://doi.org/10.1016/j.lfs.2005.05.059
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skinJournal of Dermatological Science, 2005
- Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80Life Sciences, 2005
- Effects of cannabinoid receptor‐2 activation on accelerated gastrointestinal transit in lipopolysaccharide‐treated ratsBritish Journal of Pharmacology, 2004
- Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathyProstaglandins, Leukotrienes & Essential Fatty Acids, 2002
- Fibronectin receptor integrins are involved in mast cell activationJournal of Allergy and Clinical Immunology, 1994
- Adhesion molecules as regulators of mast-cell and basophil functionImmunology Today, 1994
- A proposed autacoid mechanism controlling mastocyte behaviourInflammation Research, 1993
- Effects of antidepressant drugs on histamine-H1 receptors in the brainLife Sciences, 1984
- Agents that Release Histamine from Mast CellsAnnual Review of Pharmacology and Toxicology, 1983
- Tissue thromboplastins and histamine release from mast cellsLife Sciences, 1962